Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit–Risk Assessment

This publication has 29 references indexed in Scilit:

• Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis
  Clinical Genitourinary Cancer, 2026
• Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis
  European Urology Open Science, 2026
• Probabilistic multi-criteria decision analysis comparing robot-assisted and laparoscopic radical nephroureterectomy
  Journal of Robotic Surgery, 2026
• LBA93 First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL
  Annals of Oncology, 2025
• Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma
  Annals of Oncology, 2025
• Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma
  European Urology, 2025
• Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
  Critical Reviews in Oncology/Hematology, 2022
• Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis
  Journal of Clinical Epidemiology, 2018
• Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force
  Value in Health, 2016
• A stochastic multicriteria model for evidence‐based decision making in drug benefit‐risk analysis
  Statistics in Medicine, 2011